First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis.

导出 OA

翻译打印收藏纠错

作者： Sophie,Glatt ^[1] ; Eric,Helmer ^[1] ; Birgit,Haier ^[2] ; Foteini,Strimenopoulou ^[1] ; Graham,Price ^[1] ; Pavan,Vajjah ^[1] ; Olivier A,Harari ^[1] ; John,Lambert ^[3] ; Stevan,Shaw ^[1]

作者单位： UCB Pharma, Slough, UK. ^[1] UCB Pharma, Monheim, Germany. ^[2] PAREXEL International, Middlesex, UK. ^[3]

关键词 UCB4940 anti-IL17A anti-IL17F bimekizumab interleukin-17 psoriasis

主题词成年人(Adult);老年人(Aged);剂量效应关系, 药物(Dose-Response Relationship, Drug);双盲法(Double-Blind Method);女(雌)性(Female);人类(Humans);白细胞介素17(Interleukin-17);男(雄)性(Male);中年人(Middle Aged);银屑病(Psoriasis);疾病严重程度指数(Severity of Illness Index);治疗结果(Treatment Outcome);青年人(Young Adult)

DOI 10.1111/bcp.13185

PMID 27859546

发布时间 2023-11-12

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览50

British journal of clinical pharmacology

2017年83卷5期

991-1001页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis.

British journal of clinical pharmacology

相似文献

British journal of clinical pharmacology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis.

British journal of clinical pharmacology

相似文献

British journal of clinical pharmacology

相关期刊

检索历史清除